Astellas Pharma
4503.T
#1071
Rank
$17.44 B
Marketcap
$9.73
Share price
1.33%
Change (1 day)
-41.98%
Change (1 year)

P/E ratio for Astellas Pharma (4503.T)

P/E ratio as of May 2024 (TTM): 23.3

According to Astellas Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.2587. At the end of 2022 the company had a P/E ratio of 26.7.

P/E ratio history for Astellas Pharma from 2009 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202226.7-7.23%
202128.835.18%
202021.333.87%
201915.925.14%
201812.7-20.92%
201716.1-2.61%
201616.5-18.25%
201520.2-33.74%
201430.5103.23%
201315.0-45.73%
201227.766.7%
201116.6-0.5%
201016.735.86%
200912.3

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.